Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome

Gynecological Endocrinology

Volumn 20, Issue 5, 2005, Pages 258-263

  Yilmaz, Murat ^a,c   Biri, Aydan ^b   Bukan, Neslihan ^b   Karakoç, Ayhan ^b   Sancak, Banu ^b   Törüner, Füsun ^b   Paşaoǧlu, Hatice ^b  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Cardiovascular disease; Homocysteine; Insulin resistance; Lipoprotein; Polycystic ovary syndrome

Indexed keywords

ANDROSTENEDIONE; APOLIPOPROTEIN A; APOLIPOPROTEIN B; CYANOCOBALAMIN; FOLIC ACID; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; PRASTERONE SULFATE; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RISK FACTOR;

17-ALPHA-HYDROXYPROGESTERONE; ADULT; APOLIPOPROTEINS A; APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; FOLLICLE STIMULATING HORMONE; HOMOCYSTEINE; HUMANS; INSULIN; LIPOPROTEIN(A); LIPOPROTEINS; LUTEINIZING HORMONE; OBESITY; POLYCYSTIC OVARY SYNDROME; TESTOSTERONE; TRIGLYCERIDES;

EID: 21244477051     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590400027265     Document Type: Article

References (37)

1. Frank S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-61.
2. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876-80.
3. Dunaif A, Segal K, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74.
4. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
5. Ehrman DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women polycystic ovary syndrome. Diabetes Care 1999;22:141-6.
6. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association. Endocr Rev 2003;24:302-12.
7. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000;52:595-600.
8. Fonseca V, Guba SC, Fink LM. Hyperhomocysteinemia and the endocrine system: implications for atherosclerosis and thrombosis. Endocr Rev 1999;20:738-59.
9. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-50.
10. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
11. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, Meier B, Turi ZG, Hess OM. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001;345:1593-600.
12. Guzick DS. Cardiovascular risk in women with polycystic ovarian syndrome. Semin Reprod Endocrinol 1996;14:45-9.
13. Birdsall MA, Farquar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 1997;126:32-5.
14. Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 1998;51:415-22.
15. Yarali H, Yildirir A, Aybar F, Kabakci G, Bukulmez O, Akgul E, Oto A. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001;76:511-16.
16. Vrbikova J, Bicikova M, Tallova J, Hill M, Starka L. Homocysteine and steroid levels in metformin-treated women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2002;110:74-7.
17. Randeva HS, Lewandowski KC, Drzewoski J, Brooke-Wavell K, O'Callaghan C, Czupryniak L, Hillhouse WE, Prelevic MG. Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome J Clin Endocrinol Metab 2002;87:4496-501.
18. Loverro G, Lorusso F, Mei L, Depalo R, Cormio G, Selvaggi L. The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest 2002;53:157-62.
19. Wijeyaratne CN, Nirantharakumar K, Balen AH, Barth JH, Sheriff R, Belchetz PE. Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity? Clin Endocrinol (Oxf) 2004;60:560-7.
20. Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-El R. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod 2003;18:721-7.
21. Wild RA, Painter RD, Coulson PB, Carruth KB, Ranney RB. Lipoprotein lipid concentrations as cardiovascular risk in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 1985;61:946-50.
22. Homburg R. What is polycystic ovarian syndrome? Hum Reprod 2003;17:2495-9.
23. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-7.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
25. De Leo V, Marca A, Petraglia F. Insulin lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003;24:633-67.
26. Orio F, Palomba S, Di Biase S, Calao A, Tauchmanova L, Savastano S, Labella D, Russo T, Zullo F, Lombardi G. Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:673-9.
27. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004;89:2160-5.
28. Sills ES, Genton MG, Perloe M, Schattman GL, Bralley JA, Tucker MJ. Plasma homocysteine, fasting insulin, and androgen patterns among women with polycystic ovaries and infertility. J Obstet Gynaecol Res 2001;27:163-8.
29. De Pergola G, Pannaciulli N, Zamboni M, Minenna A, Brocco G, Sciaraffa M, Bosello O, Giorgino R. Homocysteine plasma levels are independently associated with insulin resistance in normal weight, overweight and obese premenopausal women. Diabetes Nutr Metab 2001;14:253-8.
30. Tallova J, Tomandl J, Bicikova M, Hill M. Changes of plasma total homocysteine levels during the menstrual cycle. Eur J Clin Invest 1999;129:1041-4.
31. Brattström L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 1994;236:633-41.
32. Guttormsen AB, Schneede J, Fiskerstrand T, Ueland PM, Refsum HM. Plasma concentrations homocysteine and other aminothiol compounds are related to food intake in healthy human subjects. J Nutr 1994;124:1934-41.
33. Glueck CJ, Shaw P, Lang JE, Tracy T, Sieve-Smith L, Wang. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 1995;75:132-6.
34. Tonstad S, Refsum H, Ueland PM. Association between plasma total homocysteine and parental history of cardiovascular disease in children with familial hypercholesterolemia. Circulation 1997;96:1803-8.
35. Ajabnoor MA, Al-Ama MN, Banjar Z, Rafee AA, Sheweita SA. Homocysteine level and other biochemical parameters in cardiovascular disease patients with diabetes mellitus. Med Sci Monit 2003;9:523-7.
36. Soysal D, Savas S, Susam I, Cevik C, Goldeli E, Sozmen E, Guneri S. The association of plasma homocysteine, coronary risk factors and serum nitrite in patients with coronary artery disease, vascular syndrome X and healthy subjects. Anadolu Kardiyol Derg 2003;3:26-36.
37. Buccianti G, Baragetti I, Bamonti F, Furiani S, Dorighet V, Patrosso C. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. J Nephrol 2004;17:405-10.